We further analyzed the differences in the immune microenvironment between HBV+ ESCC patients and HBV– ESCC patients to explore the mechanism underlying their different response to anti-PD-1 therapy. The gene discussed is PDCD1; the disease is esophageal squamous cell carcinoma.